학술논문
Continuous glucose monitoring for the routine care of type 2 diabetes mellitus.
Document Type
Academic Journal
Author
Ajjan RA; The LIGHT Laboratories, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK.; Battelino T; Faculty of Medicine, University of Ljubljana Medical Centre, Ljubljana, Slovenia.; Cos X; DAP Cat Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gorina, Barcelona, Spain.; Del Prato S; Section of Diabetes and Metabolic Diseases, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.; Philips JC; Diabetes, Nutrition, and Metabolic Disorders, University of Liège, Liège, Belgium.; Meyer L; Department of Endocrinology, Diabetes and Nutrition, University Hospital, Strasbourg, France.; Seufert J; Division of Endocrinology and Diabetology, Department of Medicine II, Medical Centre, University of Freiburg, Freiburg, Germany.; Seidu S; Leicester Real World Evidence Unit, Diabetes Research Centre, University of Leicester, Leicester, UK. sis11@leicester.ac.uk.
Source
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101500078 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1759-5037 (Electronic) Linking ISSN: 17595029 NLM ISO Abbreviation: Nat Rev Endocrinol Subsets: MEDLINE
Subject
Language
English
Abstract
Although continuous glucose monitoring (CGM) devices are now considered the standard of care for people with type 1 diabetes mellitus, the uptake among people with type 2 diabetes mellitus (T2DM) has been slower and is focused on those receiving intensive insulin therapy. However, increasing evidence now supports the inclusion of CGM in the routine care of people with T2DM who are on basal insulin-only regimens or are managed with other medications. Expanding CGM to these groups could minimize hypoglycaemia while allowing efficient adaptation and escalation of therapies. Increasing evidence from randomized controlled trials and observational studies indicates that CGM is of clinical value in people with T2DM on non-intensive treatment regimens. If further studies confirm this finding, CGM could soon become a part of routine care for T2DM. In this Perspective we explore the potential benefits of widening the application of CGM in T2DM, along with the challenges that must be overcome for the evidence-based benefits of this technology to be delivered for all people with T2DM.
(© 2024. Springer Nature Limited.)
(© 2024. Springer Nature Limited.)